Combination with HSP90 inhibitors is evaluated as an effective strategy to overcome the resistance of JAK2 inhibitors in fibrotic diseases and myeloproliferative neoplasms (Zhang et al., 2017). Here, HSP90AB1 is linked to myeloproliferative neoplasm.